QIAGEN Launches artus Prep&Amp as CE-Marked SARS-CoV-2 Test Offering up to Threefold Increase in Daily Lab Testing Capacity
April 20 2021 - 4:05PM
Business Wire
- QIAGEN’s innovative Prep&Amp technology integrates sample
preparation and detection in a single kit, enabling throughput of
more than 670 tests per PCR cycler in an eight-hour shift
- CE-IVD marking for Europe and other countries worldwide, EUA
(Emergency Use Application) submission made in the U.S.
- Streamlined workflow cuts costs and plastic usage – offering
time to result of about two hours
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today
announced the launch of the artus® SARS-CoV-2 Prep&Amp UM Kit
which uses a liquid based sample preparation technology to simplify
and increase COVID-19 testing throughput. The artus® SARS-CoV-2
Prep&Amp UM Kit has been CE-IVD registered for use in the
European Union and other markets and an application for Emergency
Use Authorization (EUA) has been submitted to the FDA, allowing
commercialization via notification in the US.
QIAGEN’s innovative artus® SARS-CoV-2 Prep&Amp UM Kit
integrates a liquid-based sample preparation that takes no more
than two minutes with the provided real-time PCR assay. The kit
uses common transport media like Universal Transport Media (UTM™)
as the starting material, and provide all reagents required for
sample to result on suspected SARS-CoV-2 patient samples.
The streamlined workflow delivers results considerably faster
than standard extraction-based Real-Time PCR processes – and can
support up to 672 samples per cycler in an eight-hour shift.
Additionally, due to the short workflow the quantity and volume of
waste created is considerably lower.
The artus® SARS-CoV-2 Prep&Amp UM Kit is based on the same
technology that was launched in October 2020 as QIAprep& for
research applications. It has since proved its ability to detect
the SARS-CoV-2 pathogen to be similar to regular PCR workflows.
“The launch of our artus® SARS-CoV-2 Prep&Amp test is an
important step as it expands our portfolio of testing solutions for
COVID-19,” said Jean-Pascal Viola, Senior Vice President, Head of
the Molecular Diagnostics Business Area and Corporate Business
Development at QIAGEN. “We continue to see the need for a large
volume of PCR tests as COVID-19 cases continue around the world –
and our novel technology will enable clinical labs to drastically
increase testing capacity with existing infrastructure. It is also
an exciting and versatile technology with additional potential
applications.”
QIAGEN has one of the most comprehensive SARS-CoV-2 research and
testing portfolios. It includes sample preparation innovations like
artus® SARS-CoV-2 Prep&Amp, syndromic testing solution
QIAstat-Dx, high throughput PCR with its NeuMoDx devices, QIAcuity
digital PCR for wastewater testing applications, QIAreach digital
antibody and antigen tests, and T-cell research solutions based on
QIAGEN’s QuantiFERON IGRA technology. QIAGEN also has a range of
products for NGS research into the SARS-CoV-2 virus and
bioinformatic services and databases such as QDI (QIAGEN Digital
Insights).
QIAGEN continues to add novel solutions to support laboratories
combatting the pandemic and to provide experts with tools to learn
more about the virus and drive forward research – as well as
providing solutions that will be relevant beyond the current
pandemic.
More information on artus® SARS-CoV-2 Prep&Amp UM Kit can be
found here.
For an overview of QIAGEN’s coronavirus testing solutions,
please visit http://www.qiagen.com/coronavirus.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading
global provider of Sample to Insight solutions that enable
customers to gain valuable molecular insights from samples
containing the building blocks of life. Our sample technologies
isolate and process DNA, RNA and proteins from blood, tissue and
other materials. Assay technologies make these biomolecules visible
and ready for analysis. Bioinformatics software and knowledge bases
interpret data to report relevant, actionable insights. Automation
solutions tie these together in seamless and cost-effective
workflows. QIAGEN provides solutions to more than 500,000 customers
around the world in Molecular Diagnostics (human healthcare) and
Life Sciences (academia, pharma R&D and industrial
applications, primarily forensics). As of December 31, 2020, QIAGEN
employed approximately 5,600 people in over 35 locations worldwide.
Further information can be found at http://www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press release may be
considered forward-looking statements within the meaning of Section
27A of the U.S. Securities Act of 1933, as amended, and Section 21E
of the U.S. Securities Exchange Act of 1934, as amended. To the
extent that any of the statements contained herein relating to
QIAGEN's products, including those products used in the response to
the COVID-19 pandemic, timing for launch and development, marketing
and/or regulatory approvals, financial and operational outlook,
growth and expansion, collaborations markets, strategy or operating
results, including without limitation its expected adjusted net
sales and adjusted diluted earnings results, are forward-looking,
such statements are based on current expectations and assumptions
that involve a number of uncertainties and risks. Such
uncertainties and risks include, but are not limited to, risks
associated with management of growth and international operations
(including the effects of currency fluctuations, regulatory
processes and dependence on logistics), variability of operating
results and allocations between customer classes, the commercial
development of markets for our products to customers in academia,
pharma, applied testing and molecular diagnostics; changing
relationships with customers, suppliers and strategic partners;
competition; rapid or unexpected changes in technologies;
fluctuations in demand for QIAGEN's products (including
fluctuations due to general economic conditions, the level and
timing of customers' funding, budgets and other factors); our
ability to obtain regulatory approval of our products; difficulties
in successfully adapting QIAGEN's products to integrated solutions
and producing such products; the ability of QIAGEN to identify and
develop new products and to differentiate and protect our products
from competitors' products; market acceptance of QIAGEN's new
products and the integration of acquired technologies and
businesses; actions of governments, global or regional economic
developments, weather or transportation delays, natural disasters,
political or public health crises, including the breadth and
duration of the COVID-19 pandemic and its impact on the demand for
our products and other aspects of our business, or other force
majeure events; as well as the possibility that expected benefits
related to recent or pending acquisitions may not materialize as
expected; and the other factors discussed under the heading “Risk
Factors” contained in Item 3 of our most recent Annual Report on
Form 20-F. For further information, please refer to the discussions
in reports that QIAGEN has filed with, or furnished to, the U.S.
Securities and Exchange Commission.
Category: Corporate
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210420006096/en/
QIAGEN Investor Relations John Gilardi, +49 2103
29 11711 Phoebe Loh, +49 2103 29 11457 ir@QIAGEN.com
Public Relations Thomas Theuringer, +49 2103 29 11826
Robert Reitze, +49 2103 29 11676 pr@QIAGEN.com
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From Apr 2024 to May 2024
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From May 2023 to May 2024